UK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven cell conversion programmes. The funding from the UK’s innovation agency will be ...

CAMBRIDGE, United Kingdom and TOKYO, July 5, 2022 /PRNewswire/ -- Mogrify Limited (CEO: Darrin M. Disley, Ph.D., "Mogrify ® "), a biopharmaceutical company transforming the lives of patients through a ...

CAMBRIDGE, England & BRISBANE, Calif.--(BUSINESS WIRE)-- Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell ...

Cambridge, UK-based biotech startup Mogrify, which is working on systematizing the development of novel cell therapies in areas such as regenerative medicine, has closed an initial $16 million Series ...

Sangamo Therapeutics has struck a deal with Mogrify to gain access to a source of cells for use in its allogeneic CAR-Treg therapies. The agreement sees Sangamo pay an upfront fee to get Mogrify to ...

Cell Mogrify (Mogrify), has been granted funding by the UK’s innovation agency, Innovate UK, to accelerate regenerative cell therapies. United Kingdom-based company, Cell Mogrify (Mogrify), has been ...

Mogrify Limited (Mogrify ®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, today announced it had secured the ...

Darrin M Disley, PhD, DSc, OBE, appointed as CEO New investment from Ahren Innovation Capital, 24Haymarket and Dr Disley Mogrify's technology enables the conversion of any mature cell type into any ...

Assignment of rights in foundational patent underpinning the Company's direct cell conversion technology Exclusive license from MRC Laboratory of Molecular Biology of rights to enhanced version of ...

“Mogrify is delighted to announce its second commercial deal with a US biopharma and the first in the exciting field of T cell immunotherapy,” said Dr. Darrin M. Disley OBE, CEO, Mogrify. “The ...